SCHEMBL9924029

SCHEMBL9924029

CCc1c(NC(=O)OC(C)(C)C)nc2c(C(F)(F)F)cccn12

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.44
LMNA P02545 1/20 0.44
NR1H3 Q13133 6/20 0.39
NR1H2 P55055 5/20 0.39
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
CYP1A2 P05177 2/20 0.36
CYP2C9 P11712 1/20 0.36
USP7 Q93009 1/20 0.36
GPR139 Q6DWJ6 1/20 0.36
SCN9A Q15858 3/20 0.35
RXFP1 Q9HBX9 1/20 0.35
RAB9A P51151 1/20 0.34
CACNA1H O95180 1/20 0.34
CACNA1B Q00975 1/20 0.34
CACNA1C Q13936 1/20 0.34
BRD4 O60885 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9893189 0.86 TP53 (0.42) POLBNR1H3NR1H2TP53MAPT
SCHEMBL9924030 0.76 KDM4E (0.45) NR1H3NR1H2TP53MAPTCYP1A2
SCHEMBL30871442 0.74 POLB (0.39) POLBLMNACYP1A2CYP2C9GPR139
SCHEMBL9893228 0.74 USP7 (0.41) NR1H3NR1H2TP53MAPTCYP1A2
SCHEMBL9893321 0.72 NR1H3 (0.45) LMNANR1H3NR1H2MAPT
SCHEMBL9893313 0.72 NR1H3 (0.42) NR1H3NR1H2MAPT
SCHEMBL9923891 0.71 SMN1; SMN2 (0.42) LMNATP53CYP1A2CYP2C9GPR139
SCHEMBL9942095 0.71 USP7 (0.54) NR1H3NR1H2USP7BRD4
SCHEMBL30871496 0.70 MEN1 (0.36) POLBLMNACYP1A2CYP2C9GPR139
SCHEMBL5466767 0.70 LMNA (0.51) POLBLMNASCN9ARXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9067935-B2 Imidazo[1,2-α]pyridine sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2015-06-30 US disclosed
US-9067935-B2 Imidazo[1,2-α]pyridine sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2015-06-30 US disclosed
US-20140088098-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2014-03-27 US disclosed
US-20140088098-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2014-03-27 US disclosed
US-20120149699-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149699-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPV1, TRPM2 POLB 4591/4885LMNA 3025/4885NR1H3 2171/4885
US-20140088098-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPV1, TRPM2 POLB 4591/4885LMNA 3025/4885NR1H3 2171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.